PGPIPN
- Category
- Specialized Research
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A casein-derived hexapeptide sold as an immune modulator, said to boost macrophage activity and calm inflammation through mechanisms whose receptor targets remain unconfirmed. Anti-cancer, liver-protective, and chemo-synergy claims rest on low-confidence or speculative animal and cell data. No human trials exist, there is no safety data, and immune stimulation is a theoretical concern in autoimmune disease. Not an approved drug in the US; supply consists of unregulated products sold online.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
PGPIPN is a six-amino-acid peptide naturally released during the digestion of milk protein (beta-casein). First identified in the late 1980s by French researchers, it was shown to boost immune cell activity and protect mice against lethal bacterial infections. Its three proline residues make it unusually resistant to digestive enzymes, with preliminary mouse blood detection reported without underlying data; human absorption remains unestablished. Modern research has expanded its profile into anti-cancer and liver-protective applications.
How it works in the body
A hexapeptide from casein that modulates the immune system. It enhances macrophage phagocytosis and macrophage function while reducing excessive inflammatory cytokine production. Its receptor targets remain unconfirmed; opioid-receptor findings cited in the discussion concern other casein peptides.
Research overview
PGPIPN research spans four decades across three main areas. The original 1980s work (Migliore-Samour & Jolles, Paris) established it as an immune booster that enhances macrophage activity and lymphocyte growth. Since the 2010s, a dedicated program at Anhui Medical University (China) has shown it suppresses ovarian cancer cell growth in mice while sparing normal cells (4 publications, 2013-2021), and protects against alcoholic liver disease by reducing oxidative stress and fat accumulation (2 publications, 2017-2020). A notable feature is that PGPIPN is detected in blood within one hour of oral dosing in mice (83.6 ng/mL). However, all evidence is preclinical -- no human clinical trials have been conducted -- and the anti-cancer and liver research comes from a single group.
Who researches PGPIPN?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching experimental oncology peptides
Studied for effects on cancer cell targeting or tumor biology in preclinical research.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
No human safety data exists
HighPubMed esearch 'PGPIPN' = 6 records, all preclinical; no ClinicalTrials.gov entries
No standardized pharmaceutical-grade product available
HighAbsence of FDA/EMA approval
Potential immunostimulatory effects may be contraindicated in autoimmune conditions
TheoreticalPMID 16925862 (suppression of PMA-stimulated porcine macrophages, ex vivo)
Dairy allergen origin
LowSequence identity with bovine beta-casein f(63-68), stated in PMID 16925862 and PMID 23593287
Unknown effects on healthy tissue at high systemic concentrations
ModeratePMID 23593287 (single study); no published toxicology for PGPIPN in any species
Potential interaction with cancer treatment protocols
ModeratePMID 34539881
Interaction summary(5)
Rated by direction with this peptide
Cisplatin (and other platinum chemotherapeutics)
SynergisticTheoreticalIn vitro only: PGPIPN increased cisplatin-induced growth inhibition and apoptosis in sensitive SKOV3/COC1, their DDP-resistant sublines and primary patient cells, by suppressing HSF1/HSP70, MDR1 and ERCC1; the effect was reversed by the HSP70 inhibitor PFTmu. Never tested in an animal or a human. Extension beyond cisplatin to 'other platinums' is inference, not data. Any real-world combination is investigational and must be oncologist-supervised.
PMID 34539881 (J Cancer 2021)
Ethanol / alcohol
ProtectiveLowShown in two mouse studies from the same group: in chronic alcoholic fatty liver and acute alcoholic liver injury models PGPIPN dose-dependently reduced steatosis, transaminase elevation, inflammatory cytokines, oxidative stress and ER stress, with glutathione as positive control. Animal-only, one research group; no human data, so this must not be read as licence to drink alongside the peptide.
PMID 29152143; PMID 32705158
MDR1/P-glycoprotein substrate drugs (e.g. doxorubicin, paclitaxel, digoxin)
CautionTheoreticalMDR1 downregulation was measured only inside drug-resistant ovarian cancer cells, not in the intestinal, hepatic, renal or blood-brain-barrier P-gp that actually governs systemic exposure to these drugs. The inference that PGPIPN could raise P-gp substrate levels or toxicity is therefore two steps removed from the data and has never been tested in an intact organism or in humans.
PMID 34539881 (tumour-cell MDR1 expression only; no PK or transporter study exists)
HSP90/HSF1-targeting agents
SynergisticTheoreticalPathway-overlap inference only. PGPIPN demonstrably suppresses the HSF1/HSP70 heat-shock axis in ovarian cancer cells - the same stress-response pathway targeted by HSF1 and HSP90 inhibitors - so additive pathway suppression is plausible. No co-administration study with any HSP90 or HSF1 inhibitor has ever been published.
PMID 34539881 (HSF1/HSP70 suppression); no co-administration data
Immunosuppressants (transplant regimens, corticosteroids, biologics)
CautionTheoreticalThe one primary immunology study shows PGPIPN suppressing, not stimulating, activated porcine macrophage function (u-PA system and superoxide production) ex vivo, and only in the 1-2 week post-weaning window. The plausible concern is therefore additive immunosuppression rather than opposition to it - though with a single ex vivo animal study and no lymphocyte data the direction is not established either way. No interaction study exists.
PMID 16925862 (Br J Nutr 2006, ex vivo porcine macrophages)
Known risks(6)
No human safety data exists
HighPGPIPN has never been administered to humans in any clinical trial. All safety inferences are extrapolated from cell culture and mouse studies. Unknown pharmacokinetics, unknown drug interactions, unknown long-term effects, and unknown dose-response in humans.
No standardized pharmaceutical-grade product available
HighAny PGPIPN obtained outside of a research setting would lack pharmaceutical quality controls. Unregulated products sold online vary in purity, residual solvent content, and endotoxin levels and are not manufactured under GMP conditions.
Potential immunostimulatory effects may be contraindicated in autoimmune conditions
ModeratePGPIPN's original characterization was as an immunostimulant — enhancing macrophage phagocytosis and lymphocyte proliferation. In individuals with autoimmune diseases, inflammatory conditions, or transplant recipients on immunosuppressants, stimulating immune activity could be harmful. This risk is theoretical but biologically plausible.
Dairy allergen origin
Low-ModeratePGPIPN is derived from bovine beta-casein, a major milk allergen. While the hexapeptide itself may be too small to trigger classical IgE-mediated allergic responses, individuals with severe casein allergy should exercise caution. Cross-reactivity risk is unknown.
Unknown effects on healthy tissue at high systemic concentrations
While PGPIPN showed minimal cytotoxicity to normal cells in culture, the in vitro selectivity window has only been characterized for hepatocytes (LO2) and fibroblasts (MEFs). Effects on other healthy tissue types (e.g., bone marrow, intestinal epithelium, immune cells at high concentrations) have not been systematically evaluated.
Potential interaction with cancer treatment protocols
PGPIPN synergizes with cisplatin and modulates HSF1/HSP70, BCL2, and MDR1 pathways. While this was beneficial in vitro, uncontrolled use alongside chemotherapy could alter drug metabolism, resistance profiles, or toxicity in unpredictable ways.
Drug interactions(5)
Cisplatin and platinum-based chemotherapeutics
Demonstrated synergistic interaction in vitro. PGPIPN enhanced cisplatin sensitivity in both drug-sensitive and drug-resistant ovarian cancer cell lines by downregulating HSF1/HSP70, MDR1, and ERCC1. While beneficial in controlled settings, unmonitored co-administration could unpredictably alter chemotherapy pharmacodynamics and toxicity.
Immunosuppressants (cyclosporine, tacrolimus, mycophenolate, corticosteroids)
Theoretical antagonistic interaction. PGPIPN is an immunostimulant that enhances macrophage phagocytosis and lymphocyte proliferation. This could counteract the intended effects of immunosuppressive medications. No clinical data available.
Other chemotherapy agents (5-FU, doxorubicin, etc.)
PGPIPN modulates BCL2/BAX apoptotic balance and drug resistance pathways (MDR1). Theoretical potential to alter the efficacy or toxicity profile of other cytotoxic agents beyond cisplatin. No data for non-platinum chemotherapies.
Immune checkpoint inhibitors (pembrolizumab, nivolumab, etc.)
Theoretical interaction. PGPIPN's immunostimulatory properties could theoretically complement or interfere with immune checkpoint blockade. No data available, but combining immunostimulants with checkpoint inhibitors carries risk of excessive immune activation.
Hepatotoxic medications
PGPIPN demonstrated hepatoprotective effects in alcohol-induced liver injury models. It is unknown whether these protective effects extend to drug-induced liver injury or whether PGPIPN might mask early signs of hepatotoxicity.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 8
- Human Studies
- 0
All published PGPIPN research consists of in vitro cell culture experiments and in vivo mouse model studies. The peptide has been tested against human ovarian cancer cell lines (SKOV3, COC1, and their cisplatin-resistant variants) and primary ovarian cancer cells from over 40 patients, as well as in xenograft nude mouse tumor models and Kunming mouse liver disease models. There are no human pharmacokinetic, safety, efficacy, or dose-finding studies. The original immunomodulation work from the 1980s was also entirely in vitro/animal. The consistent results across multiple independent cell lines and primary patient samples are encouraging, but human translation remains untested.
Researched for(8)
Rated by confidence in the evidence
Anti-ovarian cancer activity (direct tumor suppression)
LowInhibited ovarian cancer cells and reduced tumor growth in mice; no human trials yet.
PMID 23593287 (PLoS One 2013;8(4):e60701)
Inhibition of cancer cell invasion and migration
SpeculativeBlocked cancer cell invasion and migration in lab-dish studies only, no animal model tested.
PMID 26893013 (Int J Oncol 2016;48(4):1721-9)
Synergy with cisplatin (chemosensitization)
SpeculativeIncreased cisplatin sensitivity in resistant ovarian cancer cells, single lab-dish study only.
PMID 34539881 (J Cancer 2021;12(20):6081-93)
Prevention and treatment of alcoholic fatty liver disease (AFLD)
LowReduced fatty liver and oxidative stress in alcohol-fed mice; animal data only, no human trials.
PMID 29152143 (Oncotarget 2017;8(50):88079-93)
Prevention and attenuation of acute alcoholic liver injury (AALI)
SpeculativeReduced liver injury and inflammation markers in one mouse study, no human data.
PMID 32705158 (Int J Mol Med 2020;46(3):1107-17)
Immunomodulation (macrophage and lymphocyte stimulation)
Low1989 mouse study found this casein hexapeptide stimulated macrophage phagocytosis; lymphocyte data unconfirmed.
PMID 2668358 (Migliore-Samour, Floc'h, Jolles, J Dairy Res 1989;56(3):357-62) - original casein-peptide macrophage phagocytosis stimulation and Klebsiella-protection study, the actual basis for this benefit; PMID 16925862 studied the same PGPIPN sequence in porcine immune cells, but its suppression endpoints do not directly support a stimulation claim
Antioxidant and cytoprotective effects
LowLowered oxidative stress markers and boosted antioxidant enzymes in mouse and cell models.
PMID 29152143; PMID 32705158
Selective cancer cell toxicity with minimal harm to normal cells
SpeculativeSpared normal liver cells in lab tests; unreplicated finding from one full-text study.
PMID 23593287 (full-text figures only; not stated in the abstract)
Benefits(8)
Anti-ovarian cancer activity (direct tumor suppression)
Wang et al. 2013 (PLoS One, PMID 23593287) — PGPIPN inhibited SKOV3 cell proliferation in a time- and dose-dependent manner, induced apoptosis via BCL2 downregulation and BAX upregulation, and suppressed xenograft tumor growth in nude mice by 37% (low dose) to 68% (high dose), outperforming 5-FU (42% inhibition).
Inhibition of cancer cell invasion and migration
Zhao et al. 2016 (Int J Oncol, PMID 26893013) — PGPIPN inhibited ovarian cancer cell invasion (up to 29% in SKOV3, 27% in primary cells), migration, and colony formation by downregulating MTA1 and upregulating NM23H1, two key metastasis-related genes. Tested in SKOV3 cells and primary ovarian cancer cells from 37 patients.
Synergy with cisplatin (chemosensitization)
Guo et al. 2021 (J Cancer, PMID 34539881) — PGPIPN significantly increased the sensitivity of ovarian cancer cells to cisplatin (DDP), with synergistic (not merely additive) effects in drug-resistant cell lines (SKOV3/DDP, COC1/DDP). Mechanism involves HSF1/HSP70 pathway downregulation, reducing MDR1 and ERCC1 expression. Also tested in primary ovarian cancer cells from 6 patients.
Prevention and treatment of alcoholic fatty liver disease (AFLD)
Qi et al. 2017 (Oncotarget, PMID 29152143) — PGPIPN alleviated hepatic steatosis in LO2/HepG2 cell models and AFLD mice over a 12-week alcohol exposure protocol. Reduced lipid accumulation and oxidative stress dose-dependently by regulating ACC, PPAR-gamma, CHOP, and caspase-3 expression.
Prevention and attenuation of acute alcoholic liver injury (AALI)
Xu et al. 2020 (Int J Mol Med, PMID 32705158) — Oral PGPIPN (0.04-4 mg/kg) protected mice against acute ethanol-induced liver injury. Reduced serum ALT/AST, inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), triglycerides, and cholesterol. Suppressed ER stress via PERK/eIF-2alpha phosphorylation and CHOP/caspase-3 downregulation. Dose-dependent effects.
Immunomodulation (macrophage and lymphocyte stimulation)
Migliore-Samour et al. 1989 (J Dairy Research) — PGPIPN enhanced phagocytic activity of murine peritoneal macrophages against sheep red blood cells in vitro and protected mice against lethal Klebsiella pneumoniae infection in vivo. Promoted lymphocyte proliferation and red blood cell immunity in rats.
Antioxidant and cytoprotective effects
Qi et al. 2017 and Xu et al. 2020 — Across both liver disease studies, PGPIPN consistently reduced MDA (lipid peroxidation marker), enhanced SOD and GSH-Px (antioxidant enzymes), improved cellular ATP content, and reduced oxidative damage in a dose-dependent manner.
Selective cancer cell toxicity with minimal harm to normal cells
Wang et al. 2013 — PGPIPN showed no cytotoxicity to LO2 (normal hepatocytes) at any tested concentration, and only slight inhibition of MEFs (embryonic fibroblasts) at the highest dose (0.3 g/L) after 72 hours. This selectivity compares favorably to 5-FU, which showed significant toxicity to both normal and cancer cells.
Key studies(7)
PGPIPN, a therapeutic hexapeptide, suppressed human ovarian cancer growth by targeting BCL2
Original research (preclinical — in vitro + xenograft mouse model)SKOV3 cell line, primary ovarian cancer cells from 5 patients, LO2/MEF normal cells, 24 nude mice (4 groups x 6)4 weeks (in vivo xenograft), 24-72 hours (in vitro)Wang W, Gu F, Wei C, Tang Y, Zheng X, Ren M, Qin Y
PLoS One
2013
PGPIPN suppressed SKOV3 proliferation dose-dependently, induced apoptosis via BCL2 downregulation and BAX upregulation. In xenograft mice, high-dose PGPIPN (0.50 g/L IP every other day) reduced tumor volume by 68.5%, outperforming 5-FU (41.5% reduction). Minimal cytotoxicity to normal cells.
The milk-derived hexapeptide PGPIPN inhibits the invasion and migration of human ovarian cancer cells by regulating the expression of MTA1 and NM23H1 genes
Original research (preclinical — in vitro)SKOV3 cell line, primary ovarian cancer cells from 37 patients (serous adenocarcinoma, WHO grade III-IV)12-42 hours (invasion/migration assays), 12 days (colony formation)Zhao M, Wei C, Yang X, Zhou J, Wang J, Gu F, Lei T, Qin Y
International Journal of Oncology
2016
PGPIPN inhibited invasion (up to 29% in SKOV3, 27% in primary cells), migration, and colony formation of ovarian cancer cells dose-dependently. Mechanism: downregulation of MTA1 (metastasis-associated gene) and upregulation of NM23H1 (metastasis suppressor). No or slight cytotoxicity to normal cells.
Therapeutic hexapeptide (PGPIPN) prevents and cures alcoholic fatty liver disease by affecting the expressions of genes related with lipid metabolism and oxidative stress
Original research (preclinical — in vitro + mouse model)LO2/HepG2 cell culture; 60 male Kunming mice (6 groups x 10)12 weeks (chronic alcohol exposure in mice)Qi N, Liu C, Yang H, Shi W, Wang S, Zhou Y, Wei C, Gu F, Qin Y
Oncotarget
2017
PGPIPN (0.025-2.5 mg/kg/day) alleviated hepatic steatosis in both cell models and AFLD mice. Reduced lipid accumulation and oxidative stress dose-dependently by regulating ACC phosphorylation, PPAR-gamma, MDA, SOD, GSH-Px, and caspase-3. Demonstrated both preventive and therapeutic effects on alcoholic fatty liver disease.
Milk-derived hexapeptide PGPIPN prevents and attenuates acute alcoholic liver injury in mice by reducing endoplasmic reticulum stress
Original research (preclinical — mouse model)60 male Kunming mice (6 groups x 10, aged 6-8 weeks, 18-22g)10 days (acute alcohol exposure protocol)Xu Q, Xi H, Chen X, Xu Y, Wang P, Li J, Wei W, Gu F, Qin Y
International Journal of Molecular Medicine
2020
Oral PGPIPN (0.04-4 mg/kg/day) attenuated acute alcoholic liver injury dose-dependently. Reduced serum ALT/AST, inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), triglycerides, and cholesterol. Mechanism: suppressed ER stress via reduced p-PERK (Thr980) and p-eIF-2alpha (Ser51) phosphorylation, downregulated XBP-1s, CHOP, and cleaved caspase-3. The 2020 study used oral gavage; the blood-detection claim comes from preliminary 2017 work with data not shown.
Bioactive hexapeptide reduced the resistance of ovarian cancer cells to DDP by affecting HSF1/HSP70 signaling pathway
Original research (preclinical — in vitro)SKOV3, COC1, SKOV3/DDP, COC1/DDP cell lines; primary ovarian cancer cells from 6 patients24-48 hours (viability/apoptosis assays)Guo R, Xu Q, Liu L, Liu H, Liu Y, Wei W, Qin Y
Journal of Cancer
2021
PGPIPN (0.15-15 mcM) synergistically enhanced cisplatin (DDP) sensitivity in ovarian cancer cells, with greater effect in drug-resistant lines (SKOV3/DDP, COC1/DDP) than sensitive lines. Mechanism: HSF1 and HSP70 downregulation, reduced MDR1 (P-glycoprotein) and ERCC1 (DNA repair), increased G2/M arrest. HSP70 inhibitor (Pifithrin-mu) replicated effects, confirming pathway.
Construction of an anticancer fusion peptide (ACFP) derived from milk proteins and an assay of anti-ovarian cancer cells in vitro
Original research (preclinical — in vitro, recombinant expression)SKOV3 cell line24-72 hoursZhou J, Yang X, Zhang W, Wang J, Wei C, Gu F, Lei T, Qin Y
Anticancer Agents in Medicinal Chemistry
2017
Constructed ACFP fusion peptide by linking bovine lactoferricin (LfcinB) to PGPIPN via a flexible GGGGS linker and expressing it in E. coli. ACFP showed significantly lower IC50 values against SKOV3 cells than either parent peptide alone. Enhanced structural stability and anti-enzymatic hydrolysis resistance.
The milk-derived fusion peptide, ACFP, suppresses the growth of primary human ovarian cancer cells by regulating apoptotic gene expression and signaling pathways
Original research (preclinical — in vitro with primary cells)SKOV3 cell line, primary ovarian cancer cells, primary normal ovarian cells24-72 hoursZhou J, Zhao M, Tang Y, Wang J, Wei C, Gu F, Lei T, Chen Z, Qin Y
BMC Cancer
2016
The ACFP fusion peptide (LfcinB-PGPIPN) inhibited viability and promoted apoptosis in primary ovarian cancer cells by repressing bcl-xl, akt, CDC25C, and cyclinB1 while promoting bax and caspase-3 expression. Exhibited little or no cytotoxicity toward normal primary ovarian cells, demonstrating cancer-selective toxicity.
Regulation & availability
Why researchers look at it
Oral absorption was reported in a preliminary mouse experiment with data not shown; human absorption is unknown. Four decades of preclinical work show immune-boosting effects, selective killing of ovarian cancer cells while sparing normal tissue, and reversal of chemo resistance. No human trials exist; its food-derived origin (a milk protein fragment) could ease clinical translation, but oral bioavailability has not been confirmed.
- FDA status
- No FDA status whatsoever. PGPIPN has not been submitted for Investigational New Drug (IND) application, has no FDA approval, no orphan drug designation, no fast-track designation, and has not been evaluated by the FDA in any capacity. It is not listed on the FDA's bulk drug substances list (neither permitted nor prohibited for compounding) because it has never been considered for pharmaceutical use. As a naturally occurring food-derived peptide fragment from bovine casein, PGPIPN in its native context (as part of milk protein digestion) would fall under general food safety regulations rather than drug regulations. However, any therapeutic claims or isolated peptide product would require full FDA drug approval. No pharmaceutical company has announced development plans for PGPIPN as a drug candidate.
- WADA status
- PGPIPN is not specifically named in the 2026 WADA list. Pharmacological use without human therapeutic approval falls under S0 unless another section applies. S0 does not require performance-enhancing intent; food origin does not establish an exemption.
- Prescribability
- Not prescribable. PGPIPN has no FDA, EMA, or any other regulatory agency approval for any therapeutic indication. It has never entered clinical trials in humans. All published research is preclinical (cell culture and mouse models). PGPIPN is not available through compounding pharmacies, prescription drug pathways, or as an approved dietary supplement. It exists solely as a research compound. Synthesized PGPIPN (purity >99.5% by RP-HPLC) has been used in published studies but is not commercially available through standard pharmaceutical or supplement channels.
- Availability
- PGPIPN is NOT commercially available as a pharmaceutical product, dietary supplement, or over-the-counter preparation. It has no approved formulation in any market. The peptide is a research compound that has been synthesized to >99.5% purity (confirmed by RP-HPLC) for use in published studies by the Anhui Medical University group. Because PGPIPN naturally occurs in bovine milk as a product of beta-casein digestion, trace amounts are present in casein hydrolysates and fermented dairy products, though not in controlled therapeutic concentrations.
International status
EU
Not approved
US
Not FDA-approved
Worldwide
No regulatory approval in any jurisdiction
Regulatory timeline(10)
- 1984-1989Migliore-Samour, Jolles, and colleagues at Universite de Paris characterize immunostimulating peptides from human and bovine casein, including the bovine beta-casein 63-68 sequence (PGPIPN). Published in Journal of Dairy Research (1989, PMID 2668358) and earlier works.
- 1993Fiat, Migliore-Samour, Jolles et al. publish comprehensive review of biologically active peptides from milk proteins with emphasis on antithrombotic and immunomodulating activities.
- 2013-04Wang, Qin et al. at Anhui Medical University publish first modern therapeutic study: PGPIPN suppresses human ovarian cancer growth by targeting BCL2 (PLoS One, PMID 23593287). Establishes anticancer profile and begins systematic research program.
- 2016-02Zhao, Qin et al. publish PGPIPN inhibits ovarian cancer invasion/migration via MTA1/NM23H1 (Int J Oncol, PMID 26893013). Tested on primary cancer cells from 37 patients.
- 2016-03Zhou, Qin et al. publish ACFP fusion peptide (LfcinB-PGPIPN) study demonstrating enhanced anticancer activity against primary ovarian cancer cells (BMC Cancer, PMID 27012847).
- 2017-01Zhou, Qin et al. publish ACFP construction methodology and in vitro anti-ovarian cancer results (Anticancer Agents Med Chem, PMID 27357543).
- 2017-09Qi, Qin et al. publish PGPIPN prevents and cures alcoholic fatty liver disease in mice (Oncotarget, PMID 29152143). Expands therapeutic profile beyond cancer to liver disease.
- 2020-06Xu, Qin et al. publish PGPIPN attenuates acute alcoholic liver injury via ER stress reduction (Int J Mol Med, PMID 32705158). Reports oral-gavage efficacy in mice, without measuring oral bioavailability.
- 2021-08Guo, Qin et al. publish PGPIPN reduces cisplatin resistance in ovarian cancer via HSF1/HSP70 pathway (J Cancer, PMID 34539881). Most recent PGPIPN publication.
- 2026-presentNo clinical trials registered. No IND applications filed. No pharmaceutical development announced. PGPIPN remains a preclinical research compound with no regulatory pathway initiated.
Sources & FAQs
Research sources(12)
- Wang et al. 2013 — PGPIPN suppresses ovarian cancer via BCL2 targeting
- Zhao et al. 2016 — PGPIPN inhibits ovarian cancer invasion/migration via MTA1/NM23H1
- Zhou et al. 2016 — ACFP fusion peptide suppresses primary ovarian cancer cells
- Zhou et al. 2017 — Construction of ACFP fusion peptide from milk proteins
- Qi et al. 2017 — PGPIPN prevents and cures alcoholic fatty liver disease
- Xu et al. 2020 — PGPIPN attenuates acute alcoholic liver injury via ER stress reduction
- Guo et al. 2021 — PGPIPN reduces cisplatin resistance via HSF1/HSP70 pathway
- Migliore-Samour et al. 1989 — Biologically active casein peptides and immunomodulation
- Fiat et al. 1993 — Biologically active peptides from milk proteins (immunomodulation)
- Migliore-Samour & Jolles 1988 — Casein immunostimulating hexapeptide discovery
- Xiao et al. 2001 — Bovine casein peptides co-stimulate macrophages with LPS
- Silva & Malcata 2005 — Casein-derived bioactive peptides: biological effects, regulatory status
Frequently asked questions(7)
What is PGPIPN and where does it come from?
PGPIPN (Pro-Gly-Pro-Ile-Pro-Asn) is a six-amino-acid peptide derived from residues 63-68 of bovine beta-casein, one of the major proteins in cow's milk. It is released naturally during enzymatic digestion of casein and can also be produced by bacterial proteases during milk fermentation. The region of beta-casein containing PGPIPN (residues 60-68) has been called the 'strategic zone' due to its concentration of biologically active peptide sequences.
Can I get PGPIPN from drinking milk or eating dairy?
Trace amounts of PGPIPN are likely generated during normal digestion of bovine casein and during fermentation of dairy products. However, the concentrations would be far below those used in research studies (milligrams per kilogram of body weight). There is no evidence that dietary dairy consumption delivers therapeutically relevant doses of PGPIPN.
Has PGPIPN been tested in humans?
No. All published PGPIPN research has been conducted in cell culture (in vitro) and mouse models (in vivo). No human clinical trials have been conducted, registered, or announced. The peptide has never been administered to human subjects in a controlled setting.
Is PGPIPN safe?
In preclinical studies, PGPIPN has shown a favorable safety profile. It showed no cytotoxicity to normal hepatocytes (LO2) and only minimal effects on embryonic fibroblasts (MEFs) at very high concentrations. It is derived from a food protein (milk casein) and contains only natural amino acids, and the broader casein hydrolysate literature reports no adverse effects at high intakes in animals. However, no formal toxicology studies, human safety trials, or long-term safety data exist for isolated PGPIPN.
Could PGPIPN be taken orally instead of injected?
Oral use has been studied only in mice; human absorption remains unestablished. Its three proline residues make it resistant to degradation by gastrointestinal digestive enzymes (pepsin, trypsin, chymotrypsin). A 2017 paper reports preliminary blood detection in mice within one hour of oral dosing, with underlying data not shown. The 2020 liver disease study used oral gavage as the administration route without measuring oral bioavailability.
Why is most PGPIPN research focused on ovarian cancer?
The Yide Qin research group at Anhui Medical University, which has produced all modern PGPIPN publications, began investigating the peptide's anticancer effects with ovarian cancer as their primary model system. This appears to be a laboratory-specific focus rather than an inherent limitation of the peptide. PGPIPN's mechanisms (BCL2 modulation, HSF1/HSP70 pathway effects) could theoretically apply to other cancer types, but this has not been tested.
What is ACFP and how does it relate to PGPIPN?
ACFP (AntiCancer Fusion Peptide) is an engineered peptide created by linking bovine lactoferricin (LfcinB, an antimicrobial peptide from lactoferrin) to PGPIPN via a flexible GGGGS linker arm. The fusion peptide showed enhanced anti-cancer activity, improved structural stability, and greater resistance to enzymatic degradation compared to either parent peptide alone, while retaining selectivity for cancer cells over normal cells.